Apoptosis of Bone Marrow Mesenchymal Stem Cells Caused by Homocysteine via Activating JNK Signal

PLoS ONE

Volumn 8, Issue 5, 2013, Pages

  Cai, Benzhi ^a   Li, Xingda ^a   Wang, Yang ^a   Liu, Yanju ^a   Yang, Fan ^a   Chen, Hongyang ^a   Yin, Kun ^a   Tan, Xueying ^a   Zhu, Jiuxin ^a   Pan, Zhenwei ^a   Wang, Baoqiu ^a   Lu, Yanjie ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

HOMOCYSTEINE; REACTIVE OXYGEN METABOLITE; SOMATOMEDIN C; STRESS ACTIVATED PROTEIN KINASE; VASCULOTROPIN;

ANIMAL CELL; APOPTOSIS; ARTICLE; BONE MARROW MESENCHYMAL STEM CELL; CARDIOVASCULAR DISEASE; CELL STRUCTURE; CELL VIABILITY; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; HYPERHOMOCYSTEINEMIA; MEMBRANE DEPOLARIZATION; MESENCHYMAL STEM CELL; MITOCHONDRIAL MEMBRANE POTENTIAL; MOLECULAR PATHOLOGY; NONHUMAN; RAT; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ANIMALS; APOPTOSIS; BONE MARROW CELLS; CELL SHAPE; CELL SURVIVAL; ENZYME ACTIVATION; HOMOCYSTEINE; INSULIN-LIKE GROWTH FACTOR I; INTRACELLULAR SPACE; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MAP KINASE SIGNALING SYSTEM; MEMBRANE POTENTIAL, MITOCHONDRIAL; MESENCHYMAL STROMAL CELLS; PROTEIN KINASE INHIBITORS; RATS; RATS, SPRAGUE-DAWLEY; REACTIVE OXYGEN SPECIES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84877108953     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0063561     Document Type: Article

References (43)

1. Anker PS, Noort WA, Scherjon SA, Kleijburg-van der Keur C, Kruisselbrink AB, et al. (2003) Mesenchymal stem cells in human second-trimester bone marrow, liver, lung, and spleen exhibit a similar immunophenotype but a heterogeneous multilineage differentiation potential. Haematologica 88: 845-852.
2. Bianco P, Robey PG, Simmons PJ, (2008) Mesenchymal stem cells: revisiting history, concepts, and assays. Cell Stem Cell 2: 313-319 S1934-5909(08)00114-8 [pii];10.1016/j.stem.2008.03.002 [doi].
3. Majumdar MK, Thiede MA, Haynesworth SE, Bruder SP, Gerson SL, (2000) Human marrow-derived mesenchymal stem cells (MSCs) express hematopoietic cytokines and support long-term hematopoiesis when differentiated toward stromal and osteogenic lineages. J Hematother Stem Cell Res 9: 841-848 10.1089/152581600750062264 [doi].
4. Barry FP, Murphy JM, (2004) Mesenchymal stem cells: clinical applications and biological characterization. Int J Biochem Cell Biol 36: 568-584 10.1016/j.biocel.2003.11.001 [doi];S1357272503003625 [pii].
5. Ponte AL, Marais E, Gallay N, Langonne A, Delorme B, Herault O, et al. (2007) The in vitro migration capacity of human bone marrow mesenchymal stem cells: comparison of chemokine and growth factor chemotactic activities. Stem Cells 25: 1737-1745 2007-0054 [pii];10.1634/stemcells.2007-0054 [doi].
6. Kortesidis A, Zannettino A, Isenmann S, Shi S, Lapidot T, et al. (2005) Stromal-derived factor-1 promotes the growth, survival, and development of human bone marrow stromal stem cells. Blood 105: 3793-3801 2004-11-4349 [pii];10.1182/blood-2004-11-4349 [doi].
7. Tang YL, Zhao Q, Qin X, Shen L, Cheng L, et al. (2005) Paracrine action enhances the effects of autologous mesenchymal stem cell transplantation on vascular regeneration in rat model of myocardial infarction. Ann Thorac Surg 80: 229-236 S0003-4975(05)00340-1 [pii];10.1016/j.athoracsur.2005.02.072 [doi].
8. Silva GV, Litovsky S, Assad JA, Sousa AL, Martin BJ, et al. (2005) Mesenchymal stem cells differentiate into an endothelial phenotype, enhance vascular density, and improve heart function in a canine chronic ischemia model. Circulation 111: 150-156 01.CIR.0000151812.86142.45 [pii];10.1161/01.CIR.0000151812.86142.45 [doi].
9. Gnecchi M, He H, Liang OD, Melo LG, Morello F, et al. (2005) Paracrine action accounts for marked protection of ischemic heart by Akt-modified mesenchymal stem cells. Nat Med 11: 367-368 nm0405-367 [pii];10.1038/nm0405-367 [doi].
10. Yang YJ, Qian HY, Huang J, Geng YJ, Gao RL, et al. (2008) Atorvastatin treatment improves survival and effects of implanted mesenchymal stem cells in post-infarct swine hearts. Eur Heart J 29: 1578-1590 ehn167 [pii];10.1093/eurheartj/ehn167 [doi].
11. Stamm C, Liebold A, Steinhoff G, Strunk D, (2006) Stem cell therapy for ischemic heart disease: beginning or end of the road? Cell Transplant 15Suppl 1: S47-S56.
12. Toma C, Pittenger MF, Cahill KS, Byrne BJ, Kessler PD, (2002) Human mesenchymal stem cells differentiate to a cardiomyocyte phenotype in the adult murine heart. Circulation 105: 93-98.
13. Cai B, Li J, Wang J, Luo X, Ai J, Liu Y, et al. (2012) microRNA-124 regulates cardiomyocyte differentiation of bone marrow-derived mesenchymal stem cells via targeting STAT3 signaling. Stem Cells 30: 1746-1755 10.1002/stem.1154 [doi].
14. Noiseux N, Gnecchi M, Lopez-Ilasaca M, Zhang L, Solomon SD, et al. (2006) Mesenchymal stem cells overexpressing Akt dramatically repair infarcted myocardium and improve cardiac function despite infrequent cellular fusion or differentiation. Mol Ther 14: 840-850 S1525-0016(06)00214-0 [pii];10.1016/j.ymthe.2006.05.016 [doi].
15. Wisel S, Khan M, Kuppusamy ML, Mohan IK, Chacko SM, et al. (2009) Pharmacological preconditioning of mesenchymal stem cells with trimetazidine (1-[2,3,4-trimethoxybenzyl]piperazine) protects hypoxic cells against oxidative stress and enhances recovery of myocardial function in infarcted heart through Bcl-2 expression. J Pharmacol Exp Ther 329: 543-550 jpet.109.150839 [pii];10.1124/jpet.109.150839 [doi].
16. Kim HW, Haider HK, Jiang S, Ashraf M, (2009) Ischemic preconditioning augments survival of stem cells via miR-210 expression by targeting caspase-8-associated protein 2. J Biol Chem 284: 33161-33168 M109.020925 [pii];10.1074/jbc.M109.020925 [doi].
17. Falk E, Zhou J, Moller J, (2001) Homocysteine and atherothrombosis. Lipids 36Suppl: S3-11.
18. Wald DS, Law M, Morris JK, (2002) Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ 325: 1202.
19. Sipkens JA, Krijnen PA, Meischl C, Cillessen SA, Smulders YM, et al. (2007) Homocysteine affects cardiomyocyte viability: concentration-dependent effects on reversible flip-flop, apoptosis and necrosis. Apoptosis 12: 1407-1418 10.1007/s10495-007-0077-5 [doi].
20. Tsai JC, Perrella MA, Yoshizumi M, Hsieh CM, Haber E, et al. (1994) Promotion of vascular smooth muscle cell growth by homocysteine: a link to atherosclerosis. Proc Natl Acad Sci U S A 91: 6369-6373.
21. Danese S, Sgambato A, Papa A, Scaldaferri F, Pola R, et al. (2005) Homocysteine triggers mucosal microvascular activation in inflammatory bowel disease. Am J Gastroenterol 100: 886-895 AJG41469 [pii];10.1111/j.1572-0241.2005.41469.x [doi].
22. Benzhi C, Limei Z, Ning W, Jiaqi L, Songling Z, et al. (2009) Bone marrow mesenchymal stem cells upregulate transient outward potassium currents in postnatal rat ventricular myocytes. J Mol Cell Cardiol 47: 41-48 S0022-2828(09)00108-4 [pii];10.1016/j.yjmcc.2009.03.002 [doi].
23. Li JX, Shen YQ, Cai BZ, Zhao J, Bai X, et al. (2010) Arsenic trioxide induces the apoptosis in vascular smooth muscle cells via increasing intracellular calcium and ROS formation. Mol Biol Rep 37: 1569-1576 10.1007/s11033-009-9561-z [doi].
24. Chandra J, Samali A, Orrenius S (2000) Triggering and modulation of apoptosis by oxidative stress. Free Radic Biol Med 29: 323-333. S0891-5849(00)00302-6 [pii].
25. Papa S, Skulachev VP, (1997) Reactive oxygen species, mitochondria, apoptosis and aging. Mol Cell Biochem 174: 305-319.
26. Shen HM, Liu ZG, (2006) JNK signaling pathway is a key modulator in cell death mediated by reactive oxygen and nitrogen species. Free Radic Biol Med 40: 928-939 S0891-5849(05)00668-4 [pii];10.1016/j.freeradbiomed.2005.10.056 [doi].
27. Crisostomo PR, Wang Y, Markel TA, Wang M, Lahm T, et al. (2008) Human mesenchymal stem cells stimulated by TNF-alpha, LPS, or hypoxia produce growth factors by an NF kappa B- but not JNK-dependent mechanism. Am J Physiol Cell Physiol 294: C675-C682 00437.2007 [pii];10.1152/ajpcell.00437.2007 [doi].
28. Gnecchi M, He H, Noiseux N, Liang OD, Zhang L, et al. (2006) Evidence supporting paracrine hypothesis for Akt-modified mesenchymal stem cell-mediated cardiac protection and functional improvement. FASEB J 20: 661-669 20/6/661 [pii];10.1096/fj.05-5211com [doi].
29. Korbling M, Estrov Z, (2003) Adult stem cells for tissue repair- a new therapeutic concept? N Engl J Med 349: 570-582 10.1056/NEJMra022361 [doi];349/6/570 [pii].
30. Malinowska J, Nowak P, Olas B, (2009) [Hyperhomocysteinemia and the disturbance of haemostasis-facts and mythes]. Pol Merkur Lekarski 27: 413-418.
31. Suhara T, Fukuo K, Yasuda O, Tsubakimoto M, Takemura Y, et al. (2004) Homocysteine enhances endothelial apoptosis via upregulation of Fas-mediated pathways. Hypertension 43: 1208-1213 10.1161/01.HYP.0000127914.94292.76 [doi];01.HYP.0000127914.94292.76 [pii].
32. Guthikonda S, Haynes WG, (1999) Homocysteine as a novel risk factor for atherosclerosis. Curr Opin Cardiol 14: 283-291.
33. Cai B, Gong D, Chen N, Li J, Wang G, et al. (2011) The negative inotropic effects of homocysteine were prevented by matrine via the regulating intracellular calcium level. Int J Cardiol 150: 113-115 S0167-5273(11)00378-0 [pii];10.1016/j.ijcard.2011.04.031 [doi].
34. Cai B, Shan L, Gong D, Pan Z, Ai J, et al. (2009) Homocysteine modulates sodium channel currents in human atrial myocytes. Toxicology 256: 201-206 S0300-483X(08)00572-6 [pii];10.1016/j.tox.2008.11.020 [doi].
35. Cai BZ, Gong DM, Liu Y, Pan ZW, Xu CQ, et al. (2007) Homocysteine inhibits potassium channels in human atrial myocytes. Clin Exp Pharmacol Physiol 34: 851-855 CEP4671 [pii];10.1111/j.1440-1681.2007.04671.x [doi].
36. Cai B, Gong D, Pan Z, Liu Y, Qian H, et al. (2007) Large-conductance Ca2+-activated K+ currents blocked and impaired by homocysteine in human and rat mesenteric artery smooth muscle cells. Life Sci 80: 2060-2066 S0024-3205(07)00242-1 [pii];10.1016/j.lfs.2007.03.003 [doi].
37. Kowaltowski AJ, Vercesi AE (1999) Mitochondrial damage induced by conditions of oxidative stress. Free Radic Biol Med 26: 463-471. S0891-5849(98)00216-0 [pii].
38. Kim HJ, Chakravarti N, Oridate N, Choe C, Claret FX, et al. (2006) N-(4-hydroxyphenyl)retinamide-induced apoptosis triggered by reactive oxygen species is mediated by activation of MAPKs in head and neck squamous carcinoma cells. Oncogene 25: 2785-2794 1209303 [pii];10.1038/sj.onc.1209303 [doi].
39. Kang YH, Lee SJ, (2008) The role of p38 MAPK and JNK in Arsenic trioxide-induced mitochondrial cell death in human cervical cancer cells. J Cell Physiol 217: 23-33 10.1002/jcp.21470 [doi].
40. Chavarria T, Rodriguez-Nieto S, Sanchez-Jimenez F, Quesada AR, Medina MA (2003) Homocysteine is a potent inhibitor of human tumor cell gelatinases. Biochem Biophys Res Commun 303: 572-575. S0006291X03003826 [pii].
41. Zhang C, Cai Y, Adachi MT, Oshiro S, Aso T, et al. (2001) Homocysteine induces programmed cell death in human vascular endothelial cells through activation of the unfolded protein response. J Biol Chem 276: 35867-35874 10.1074/jbc.M100747200 [doi];M100747200 [pii].
42. Levrand S, Pacher P, Pesse B, Rolli J, Feihl F, et al. (2007) Homocysteine induces cell death in H9C2 cardiomyocytes through the generation of peroxynitrite. Biochem Biophys Res Commun 359: 445-450 S0006-291X(07)01076-5 [pii];10.1016/j.bbrc.2007.05.147 [doi].
43. Chang PY, Lu SC, Lee CM, Chen YJ, Dugan TA, et al. (2008) Homocysteine inhibits arterial endothelial cell growth through transcriptional downregulation of fibroblast growth factor-2 involving G protein and DNA methylation. Circ Res 102: 933-941 CIRCRESAHA.108.171082 [pii];10.1161/CIRCRESAHA.108.171082 [doi].